A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)

Clinical trial NCT07227402 · RECRUITING

Trial details

NCT number: NCT07227402
Sponsor: Merck Sharp & Dohme LLC
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Renal Cell Carcinoma

Start date: 2025-11-26
Primary completion: 2032-02-27
Enrollment: 904

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.